Pazopanib for the treatment of breast cancer. [Review] 

 -  2012 
<br/><br/> INTRODUCTION: Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC). AREAS COVERED: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. EXPERT OPINION: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1354-3784 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Angiogenesis Inhibitors/tu [Therapeutic Use]<br/>*Breast Neoplasms/dt [Drug Therapy]<br/>*Protein Kinase Inhibitors/tu [Therapeutic Use]<br/>*Pyrimidines/tu [Therapeutic Use]<br/>*Sulfonamides/tu [Therapeutic Use]<br/>Breast Neoplasms/ge [Genetics]<br/>Female<br/>Humans<br/>Protein-Tyrosine Kinases/ai [Antagonists & Inhibitors]<br/>Tumor Markers, Biological
<br/><br/><label>Subjects--Geographic Terms: </label><br/>Washington Cancer Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Research Support, N.I.H., Extramural<br/>Review